Shopping Cart
- Remove All
- Your shopping cart is currently empty
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody that is a naked antibody to the ADC compound Losatuxizumab vedotin, with potential anti-tumor activity for the study of advanced malignant solid tumors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | 187 € | In Stock | |
5 mg | 490 € | In Stock | |
10 mg | 786 € | In Stock | |
25 mg | 1.168 € | In Stock | |
50 mg | 1.567 € | In Stock |
Description | Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody that is a naked antibody to the ADC compound Losatuxizumab vedotin, with potential anti-tumor activity for the study of advanced malignant solid tumors. |
Targets&IC50 | EGFR vIII:0.12 nM (EC50), EGFR (WT):0.96 nM (EC50), EGFR (1-501):0.66 nM (EC50), EGFR phosphorylation:1.2 nM |
In vitro | Losatuxizumab (ABT-806) binds EGFR with EC50 values of 0.96 nM for EGFR wild type, 0.09 nM for EGFR(C271A,C283A), 0.12 nM for EGFR(vIII), and 0.66 nM for EGFR(1-501).[1] Losatuxizumab inhibited EGF-induced EGFR phosphorylation with an IC50 of 1.2 nM in the NR6 huEGFR(C271A,C283A) cell line.[2] |
In vivo | Losatuxizumab exhibits antitumor activity against multiple wild-type EGFR-expressing squamous cell carcinoma xenograft models. [1] Losatuxizumab (40 mg/kg, intraperitoneal) significantly delayed the growth of U87MGde2-7 tumors in mice. [1] Losatuxizumab (10 and 40 mg/kg, intraperitoneal) prolonged survival in a patient-derived xenograft glioblastoma (PDX GBM) model (SN0207 tumors) while decreasing pEGFR levels in tumor tissue. [1] |
Alias | ABT-806, ABT806 |
Cas No. | 1801544-27-3 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.